Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Shanghai China (2009)

Organization Overview

First Clinical Trial
2016
NCT02961725
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Bronchial Fistula (Phase 1)

Cerebral Palsy (Phase 1)

Communicable Diseases (Phase 4)

Cytomegalovirus Infections (Phase 4)

Fistula (Phase 1)

Fractures, Bone (Phase 2)

Fractures, Ununited (Phase 2)

Hematologic Diseases (Phase 4)

Infections (Phase 4)

Infertility (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Menopause, Premature (Phase 1)

Muscle Spasticity (Phase 1)

Neoplasm, Residual (Phase 1)

Pancreatic Neoplasms (Phase 1)

Parkinson Disease (Phase 1)

Primary Ovarian Insufficiency (Phase 1)

Spinal Cord Diseases (Phase 1)

Tissue Adhesions (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 8